Frequent p53 gene involvement in splenic B-cell leukemia/lymphomas of possible marginal zone origin

Luca Baldini, Nicola Stefano Fracchiolla, Lilla Marcella Cro, Dino Trecca, Lorenza Romitti, Elio Polli, Anna Teresa Maiolo, Antonino Neri

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

A phenotypic and molecular evaluation was made of 15 patients with mature B-cell leukemia/lymphoma showing exclusive spleen and bone marrow involvement. According to French-American-British criteria, these cases could not be classified as classical B-cell chronic lymphocytic leukemia, hairy cell leukemia and its variant forms, splenic lymphoma with villous lymphocytes, or leukemic phase non-Hodgkin's lymphoma (NHL; follicular or intermediate type). The immunophenotype pattern (high surface Ig and CD25 expression, and little or no reactivity with CD5, CD23, and CD11c) and cytomorphologic features of these neoplasms suggested an origin in the marginal zone of the spleen. Molecular analysis did not show any involvement of the dominantly acting oncogenes generally associated with lymphoid malignancies (c-myc, bcl-2, bcl-1, Ras), but mutations of the p53 tumor suppressor gene involving exons 5, 6, and 8 were found in 6 cases (6 of 15, 40%). In 4 cases, the p53 alterations consisted of a point mutation leading to amino acid substitution. In the remaining 2 cases, an insertion or deletion resulting in a frame-shift of the protein was observed. In all but 1 of the cases, the wild-type sequence at the mutation site was barely visible, implying the loss of the normal p53 allele in leukemic cells. All of the cases showed a clinical course compatible with that of low-grade NHL, regardless of the p53 loss/mutation. Overall, our data suggest the existence of a form of splenic B-cell leukemia/lymphoma of possible marginal zone origin in which p53 inactivation may play an important pathogenetic role.

Original languageEnglish
Pages (from-to)270-278
Number of pages9
JournalBlood
Volume84
Issue number1
Publication statusPublished - Jul 1 1994

Fingerprint

B-Cell Leukemia
p53 Genes
B-Cell Lymphoma
Genes
Cells
Mutation
Spleen
Hairy Cell Leukemia
Lymphocytes
B-Cell Chronic Lymphocytic Leukemia
Amino Acid Substitution
Tumor Suppressor Genes
Oncogenes
Point Mutation
Non-Hodgkin's Lymphoma
Tumors
Exons
Lymphoma
Neoplasms
Bone

ASJC Scopus subject areas

  • Hematology

Cite this

Frequent p53 gene involvement in splenic B-cell leukemia/lymphomas of possible marginal zone origin. / Baldini, Luca; Fracchiolla, Nicola Stefano; Cro, Lilla Marcella; Trecca, Dino; Romitti, Lorenza; Polli, Elio; Maiolo, Anna Teresa; Neri, Antonino.

In: Blood, Vol. 84, No. 1, 01.07.1994, p. 270-278.

Research output: Contribution to journalArticle

@article{57fcb26e82ea4ad48759755449989247,
title = "Frequent p53 gene involvement in splenic B-cell leukemia/lymphomas of possible marginal zone origin",
abstract = "A phenotypic and molecular evaluation was made of 15 patients with mature B-cell leukemia/lymphoma showing exclusive spleen and bone marrow involvement. According to French-American-British criteria, these cases could not be classified as classical B-cell chronic lymphocytic leukemia, hairy cell leukemia and its variant forms, splenic lymphoma with villous lymphocytes, or leukemic phase non-Hodgkin's lymphoma (NHL; follicular or intermediate type). The immunophenotype pattern (high surface Ig and CD25 expression, and little or no reactivity with CD5, CD23, and CD11c) and cytomorphologic features of these neoplasms suggested an origin in the marginal zone of the spleen. Molecular analysis did not show any involvement of the dominantly acting oncogenes generally associated with lymphoid malignancies (c-myc, bcl-2, bcl-1, Ras), but mutations of the p53 tumor suppressor gene involving exons 5, 6, and 8 were found in 6 cases (6 of 15, 40{\%}). In 4 cases, the p53 alterations consisted of a point mutation leading to amino acid substitution. In the remaining 2 cases, an insertion or deletion resulting in a frame-shift of the protein was observed. In all but 1 of the cases, the wild-type sequence at the mutation site was barely visible, implying the loss of the normal p53 allele in leukemic cells. All of the cases showed a clinical course compatible with that of low-grade NHL, regardless of the p53 loss/mutation. Overall, our data suggest the existence of a form of splenic B-cell leukemia/lymphoma of possible marginal zone origin in which p53 inactivation may play an important pathogenetic role.",
author = "Luca Baldini and Fracchiolla, {Nicola Stefano} and Cro, {Lilla Marcella} and Dino Trecca and Lorenza Romitti and Elio Polli and Maiolo, {Anna Teresa} and Antonino Neri",
year = "1994",
month = "7",
day = "1",
language = "English",
volume = "84",
pages = "270--278",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - Frequent p53 gene involvement in splenic B-cell leukemia/lymphomas of possible marginal zone origin

AU - Baldini, Luca

AU - Fracchiolla, Nicola Stefano

AU - Cro, Lilla Marcella

AU - Trecca, Dino

AU - Romitti, Lorenza

AU - Polli, Elio

AU - Maiolo, Anna Teresa

AU - Neri, Antonino

PY - 1994/7/1

Y1 - 1994/7/1

N2 - A phenotypic and molecular evaluation was made of 15 patients with mature B-cell leukemia/lymphoma showing exclusive spleen and bone marrow involvement. According to French-American-British criteria, these cases could not be classified as classical B-cell chronic lymphocytic leukemia, hairy cell leukemia and its variant forms, splenic lymphoma with villous lymphocytes, or leukemic phase non-Hodgkin's lymphoma (NHL; follicular or intermediate type). The immunophenotype pattern (high surface Ig and CD25 expression, and little or no reactivity with CD5, CD23, and CD11c) and cytomorphologic features of these neoplasms suggested an origin in the marginal zone of the spleen. Molecular analysis did not show any involvement of the dominantly acting oncogenes generally associated with lymphoid malignancies (c-myc, bcl-2, bcl-1, Ras), but mutations of the p53 tumor suppressor gene involving exons 5, 6, and 8 were found in 6 cases (6 of 15, 40%). In 4 cases, the p53 alterations consisted of a point mutation leading to amino acid substitution. In the remaining 2 cases, an insertion or deletion resulting in a frame-shift of the protein was observed. In all but 1 of the cases, the wild-type sequence at the mutation site was barely visible, implying the loss of the normal p53 allele in leukemic cells. All of the cases showed a clinical course compatible with that of low-grade NHL, regardless of the p53 loss/mutation. Overall, our data suggest the existence of a form of splenic B-cell leukemia/lymphoma of possible marginal zone origin in which p53 inactivation may play an important pathogenetic role.

AB - A phenotypic and molecular evaluation was made of 15 patients with mature B-cell leukemia/lymphoma showing exclusive spleen and bone marrow involvement. According to French-American-British criteria, these cases could not be classified as classical B-cell chronic lymphocytic leukemia, hairy cell leukemia and its variant forms, splenic lymphoma with villous lymphocytes, or leukemic phase non-Hodgkin's lymphoma (NHL; follicular or intermediate type). The immunophenotype pattern (high surface Ig and CD25 expression, and little or no reactivity with CD5, CD23, and CD11c) and cytomorphologic features of these neoplasms suggested an origin in the marginal zone of the spleen. Molecular analysis did not show any involvement of the dominantly acting oncogenes generally associated with lymphoid malignancies (c-myc, bcl-2, bcl-1, Ras), but mutations of the p53 tumor suppressor gene involving exons 5, 6, and 8 were found in 6 cases (6 of 15, 40%). In 4 cases, the p53 alterations consisted of a point mutation leading to amino acid substitution. In the remaining 2 cases, an insertion or deletion resulting in a frame-shift of the protein was observed. In all but 1 of the cases, the wild-type sequence at the mutation site was barely visible, implying the loss of the normal p53 allele in leukemic cells. All of the cases showed a clinical course compatible with that of low-grade NHL, regardless of the p53 loss/mutation. Overall, our data suggest the existence of a form of splenic B-cell leukemia/lymphoma of possible marginal zone origin in which p53 inactivation may play an important pathogenetic role.

UR - http://www.scopus.com/inward/record.url?scp=0028241839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028241839&partnerID=8YFLogxK

M3 - Article

VL - 84

SP - 270

EP - 278

JO - Blood

JF - Blood

SN - 0006-4971

IS - 1

ER -